Knowles Julius
SEC insider (Form 3/4/5 filer). CIK 0001808365. Director at Keros Therapeutics, Inc. (KROS). 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 4, 2026. Located in LEXINGTON, MA.
Companies Knowles Julius has filed insider reports for
- Keros Therapeutics, Inc. (KROS): Director
Knowles Julius
CIK: 0001808365
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (40.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KROS
Keros Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 4, 2026KROS
Keros Therapeutics, Inc.
SaleDirect2.6K shares at avg. $10.73$28K - Jun 3, 2026KROS
Keros Therapeutics, Inc.
AwardDirect7.1K shares- - Nov 21, 2025KROS
Keros Therapeutics, Inc.
DispositionIndirect191.5K shares at avg. $17.75$3.4M - Nov 21, 2025KROS
Keros Therapeutics, Inc.
DispositionIndirect130.5K shares at avg. $17.75$2.3M - Jun 4, 2025KROS
Keros Therapeutics, Inc.
AwardDirect5.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 4, 2026 | KROS Keros Therapeutics, Inc. | Sale | 2,625 | $10.73 | $28,166 | Direct |
| Jun 3, 2026 | KROS Keros Therapeutics, Inc. | Award | 7,142 | - | $0 | Direct |
| Nov 21, 2025 | KROS Keros Therapeutics, Inc. | Disposition | 191,527 | $17.75 | $3,399,604 | Indirect |
| Nov 21, 2025 | KROS Keros Therapeutics, Inc. | Disposition | 130,494 | $17.75 | $2,316,269 | Indirect |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | Award | 5,250 | - | - | Direct |
1-5 of 5 transactions